Clinical trial
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
NCT00386412 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00386412 |
|---|---|
| Title | TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant |
| Official title | Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infection |
| Intervention type | Drug |
| Interventions | Valganciclovir |
| Enrollment | 132 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Oct 11, 2006 |
| Last update posted | Sep 18, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: